Although there were previous concerns about interferon contributing to depression, new research shows no correlation between depression and interferon treatment among the multiple sclerosis (MS) population.
No correlation between interferon treatment and antidepressant use was observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported.
Using Explorys Enterprise Performance Management, a HIPAA-compliant depersonalized clinical database, Matthew M. Mirsky, MS, of the Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, assessed the association of antidepressant use and disease modifying therapy (DMT) prescribed for multiple sclerosis.
A search of this database, which totals 50 million patients and spans 26 different healthcare systems, “produced a cohort of individuals diagnosed with MS in the past 3 years, on a specific DMT, who were then placed on any antidepressant,” Mirsky noted.
“Additionally, the antidepressant prevalence was tested in the MS population also on the following DMTs: interferon-B1a, interferon-B1b, combined interferon-B as ‘IFN,’ glatiramer acetate, natalizumab, fingolimod, and dimethyl fumarate,” he added. The data were then further analyzed by age and sex.
Read Full Article: Interferon Does Not Up Antidepressant Use in MS Population – MPR